Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 11/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.37 |
| ▸ | PI4KA | P42356 | 10/20 | 0.36 |
| ▸ | PI4K2B | Q8TCG2 | 10/20 | 0.36 |
| ▸ | PI4K2A | Q9BTU6 | 10/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 10/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.34 |
| ▸ | AHCY | P23526 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.32 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL667204 | 0.77 | ADORA2A (0.62) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL1868819 | 0.75 | FDPS (0.44) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL320849 | 0.75 | ADORA2A (0.41) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL15829723 | 0.75 | ADORA2A (0.37) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL5490469 | 0.75 | ADORA2A (0.37) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL24239183 | 0.71 | CYP1A2 (0.54) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL9850316 | 0.71 | ADORA2A (0.42) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL22399500 | 0.71 | ADORA2A (0.42) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL5699095 | 0.71 | FLT4 (0.46) | ADORA2AADORA1PI4KAPI4K2BPI4K2A | |
| SCHEMBL23771392 | 0.71 | YTHDC1 (0.66) | ADORA2AADORA1ADORA2BAHCYADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10253360-B2 | BNA clamp method | BNA INC. (JP) | 2019-04-09 | — | — | US | disclosed |
| EP-2902499-B1 | BNA CLAMP METHOD | BNA INC (JP) | 2018-09-12 | — | — | EP | disclosed |
| EP-2902499-A9 | BNA CLAMP METHOD | BNA Inc. (JP) | 2015-10-07 | — | — | EP | disclosed |
| US-20150240299-A1 | BNA CLAMP METHOD | BNA INC. (JP) | 2015-08-27 | — | — | US | disclosed |
| EP-2902499-A1 | BNA CLAMP METHOD | BNA Inc. (JP) | 2015-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10253360-B2 | BNA clamp method | SLC28A1, SLC28A2, NAAA | ADORA2A 746/4885ADORA1 316/4885PI4KA 4104/4885 |
| US-20150240299-A1 | BNA CLAMP METHOD | SLC28A1, SLC28A2, NAAA | ADORA2A 746/4885ADORA1 316/4885PI4KA 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.